Neuropsychological effects of direct‐acting antiviral treatment for HCV subjects: a systematic review

2021 ◽  
Author(s):  
Cassio Santos‐Lima ◽  
Breno Souza‐Marques ◽  
Flávia Vieira ◽  
Maria Isabel Schinoni ◽  
Lucas C. Quarantini ◽  
...  
Keyword(s):  
Systematic Review ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Neuropsychological Effects ◽  
Direct Acting

Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis

2018 ◽  
Vol 3 (11) ◽  
pp. 754-767 ◽  
Author(s):  
Behzad Hajarizadeh ◽  
Evan B Cunningham ◽  
Hannah Reid ◽  
Matthew Law ◽  
Gregory J Dore ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Stelliana Goutzamanis ◽  
Danielle Horyniak ◽  
Joseph S. Doyle ◽  
Margaret Hellard ◽  
Peter Higgs ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Physical Health ◽  
Antiviral Treatment ◽  
Health Benefits ◽  
Community Treatment ◽  
Physical And Mental Health ◽  
Structured Interviews ◽  
Direct Acting Antiviral ◽  
Treatment Uptake ◽  
Direct Acting

Abstract Background Novel health promotion and treatment uptake initiatives will be necessary to ensure Australia meets 2030 hepatitis C elimination targets. Increasing treatment uptake will be assisted by a better understanding of the treatment experience and patient-perceived benefits. This study describes the perceived physical health benefits from direct-acting antiviral (DAA) hepatitis C treatment among people who inject drugs in Melbourne, Australia. Methods Twenty participants were recruited from a community treatment trial and community health clinics. Semi-structured interviews were performed with each participant before, during and following treatment. Interviews focused on treatment experiences, attitudes and motivations. Interviews were recorded, transcribed and thematically analysed. Results Two themes relating to the physical experience of treatment developed; intersection between physical and mental health and “maybe it’s working”. Participants reported various physical benefits, most prominently, reduced fatigue. Reductions in fatigue resulted in instant and meaningful changes in everyday life. Some participants did experience side effects, which they described as mild. Experiencing noticeable physical benefits during treatment was perceived as validation that treatment was working. Conclusion Physical health benefits of DAA treatment may have carry-on effects on cognitive, emotional or social wellbeing and should be incorporated into how treatment is promoted to those who require it.

Changes in Serum Level of Autotaxin with Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Khaled Mohamed Hussein Abdelwahab ◽  
Shereen Abou Bakr Saleh ◽  
Ghada Abdelrahman Ahmed ◽  
Asmaa Mady Gomaa Mady
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Serum Level ◽  
Antiviral Therapy ◽  
Chronic Hepatitis C ◽  
Antiviral Treatment ◽  
Post Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting

Abstract Background Hepatitis C virus virus is global health burden and major health hazard in Egypt, since the virus is the etiological factor of chronic hepatitis. Hepatitis C virus (HCV) accounts for approximately 15%-20% cases of acute hepatitis. After acute infection, around 50% to 80% of HCV patients will develop chronic infection. Approximately, HCV infects 170 million individuals worldwide). Chronic hepatitis C (CHC) patients are at high risk to develop lifethreatening complications, including cirrhosis in 20% of cases and hepatocellular carcinoma. Objectives The aim of this study was to validate Changes in serum level of autotaxin in patients with chronic hepatitis C before and after antiviral treatment. Patients and methods This study was designed as a prospective observational cohort study to evaluate Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C before (baseline) and after (sustained virologic response week 12) treatment. This prospective study was conducted on 48 chronic HCV infected patients eligible for antiviral treatment with direct acting antivirals, agreeable to regular follow up, recruited from Hepatology and virology outpatient clinic at DMNI (Damanhour Medical National Institute) during the period from September 2018 till Mars 2019. Results This study showed that Autotaxin level significantly decreased from baseline to 12 weeks post-treatment. ATX therefore represents a novel non-invasive biomarker for liver fibrosis and a prognostic indicator of disease activity. Conclusion Serum Autotaxin was found to be higher in chronic hepatitis c and ATX levels became significantly decreased from baseline to 12 weeks post-treatment with direct acting antiviral drugs in patients achieving a SVR.

Fibrosis scores that can be used in follow-up of after direct-acting antiviral treatment

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Ceren Atasoy Tahtasakal ◽  
Ahsen Oncul ◽  
Dilek Yildiz Sevgi ◽  
Duygu Demirbas ◽  
Alper Gunduz ◽  
...  
Keyword(s):  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document